vimarsana.com

Latest Breaking News On - Axonis therapeutics - Page 1 : vimarsana.com

Antares 230+ farewell launch to fly S S Laurel Clark to ISS

Antares 230+ farewell launch to fly S S Laurel Clark to ISS
nasaspaceflight.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nasaspaceflight.com Daily Mail and Mail on Sunday newspapers.

Spherical minibrains to be grown on the International Space Station

An upcoming resupply mission to the International Space Station will include stem cells destined to be grown into tiny, 3D models of the human brain.

NASA to Discuss Science on Next Northrop Grumman Space Station Mission

NASA to Discuss Science on Next Northrop Grumman Space Station Mission
indiaeducationdiary.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiaeducationdiary.in Daily Mail and Mail on Sunday newspapers.

NASA Prepares for Next Northrop Grumman International Space Station Mission Aug 1

NASA Prepares for Next Northrop Grumman International Space Station Mission Aug 1
spacecoastdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from spacecoastdaily.com Daily Mail and Mail on Sunday newspapers.

Axonis Therapeutics Raises $5M in Funding

Axonis Therapeutics, Inc., a Cambridge, Mass.-based biotechnology company advancing breakthrough research to develop therapies for neurological disorders, secured an additional $5m in funding. The round was led by Alexandria Venture Investments with participation from R3 Bio, BoxOne Ventures and Civilization Ventures and the Christopher & Dana Reeve Foundation and Spinal Research. The company intends to use the funds to advance its novel neuromodulating technology into the clinic. Led by Joanna Stanicka, PhD, CEO, and Shane Hegarty, PhD, Chief Scientific Officer, Axonis Therapeutics is advancing breakthrough research to develop therapies for neurological disorders. The company’s pipeline includes neuron-reviving therapeutics that enable an intrinsic ability of central nervous system (CNS) neurons to resist degeneration, restore excitation/inhibition balance and regenerate. The company’s targeted indications include spinal cord injury and epilepsy, as well as broader neurodeg

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.